Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 2,745 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Systemic Clear all
Recruiting No phase listed Observational

PilotStudyAssessSafeActiveSurveillancApproachLocalThe Pa w/BrainMetsUndergoinCNSPenetratSystemicThe

NCT07827001
View directory record Official record
Conditions
Brain Cancer, Brain Cancer Metastatic, Nervous System Cancer, CNS Cancer
Interventions
Not listed
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Withdrawn No phase listed Observational

Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection

NCT00811863
View directory record Official record
Conditions
Nephrogenic Systemic Fibrosis, Renal Insufficiency
Interventions
Not listed
Lead sponsor
Guerbet
Industry
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Youngstown, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 28, 2026, 8:08 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

NCT06329401
View directory record Official record
Conditions
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease, Interstitial Lung Disease, Interstitial Lung Disease Due to Connective Tissue Disease (Disorder), Interstitial Lung Disease in Patients With Rheumatoid Arthritis, Interstitial Lung Disease With Progressive Fibrotic Phenotype in Diseases Classified Elsewhere, Hypersensitivity Pneumonitis, Interstitial Lung Disease With Systemic Sclerosis
Interventions
AP01, Placebo
Drug · Other
Lead sponsor
Avalyn Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
61
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 46 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236
View directory record Official record
Conditions
COVID-19
Interventions
INB03, Placebo
Drug
Lead sponsor
Inmune Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
9
States / cities
Jonesboro, Arkansas • Louisville, Kentucky • Kosciusko, Mississippi + 4 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Withdrawn Phase 2 Interventional

Evaluating the Efficacy and Safety of Metformin in Vitiligo

NCT05607316
View directory record Official record
Conditions
Vitiligo
Interventions
Metformin Hydrochloride
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Resatorvid in Adults With Severe Sepsis

NCT00143611
View directory record Official record
Conditions
Sepsis
Interventions
Resatorvid, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Oct 28, 2026, 8:08 AM EDT
Withdrawn Phase 1 Interventional

An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)

NCT01018238
View directory record Official record
Conditions
Inflammation, Systemic Lupus Erythematosus
Interventions
NNC 0151-0000-0000, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Lake Success, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2014 · Synced Oct 28, 2026, 8:08 AM EDT
Completed No phase listed Observational

Optimizing Clinical Use of Polymyxin B

NCT02682355
View directory record Official record
Conditions
Pneumonia, Blood Stream Infection, Urinary Tract Infections, Respiratory Tract Infection (Including Tracheobronchitis), Sepsis
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Phase 2 Interventional Results available

Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery

NCT04291508
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Critical Illness, Respiratory Failure, Sepsis
Interventions
Intravenous Acetaminophen (room temperature), Intravenous Vitamin C (refrigerated), 5% Dextrose (room temperature), 5% Dextrose refrigerated
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 34 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2024 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Not applicable Interventional

Indirect Calorimetry Usage and Effect in Ventilator-free Days and Muscle Thickness in Septic Ventilated Patients

NCT03440593
View directory record Official record
Conditions
Sepsis, Critical Illness, Respiratory Failure, Nutrition Disorders, Calorie Deficiency, Diaphragm Injury, Quadriceps Muscle Atrophy
Interventions
Caloric delivery will target results of IC measurement.
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Oct 28, 2026, 8:08 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

NCT02508649
View directory record Official record
Conditions
Septic Shock
Interventions
selepressin, placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
868 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
17
States / cities
Colorado Springs, Colorado • Idaho Falls, Idaho • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 28, 2026, 8:08 AM EDT
Active, not recruiting Not applicable Interventional

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy

NCT06055881
View directory record Official record
Conditions
Breast Carcinoma, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Cancer
Interventions
Biospecimen Collection, Surveys, Stereotactic Body Radiation Therapy (SBRT), Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Other · Radiation
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Terminated No phase listed Observational

Changes in Brain Structure Related to Systemic Chemotherapy Treatment: A Prospective Study in Individuals Diagnosed With Non-small Cell Lung Cancer Utilizing High-resolution Structural Magnetic Resonance Imaging

NCT01473693
View directory record Official record
Conditions
Non-small Cell Lung Cancer
Interventions
MRI Screening Form, MRI, Demographic / Medical Data form, MRI Screening Form, MRI. Demographic / Medical Data
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)

NCT03724916
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Anniston, Alabama • Birmingham, Alabama • La Jolla, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2024 · Synced Oct 28, 2026, 8:08 AM EDT
Recruiting Phase 2 Interventional

2-HOBA in Systemic Lupus Erythematosus

NCT07225543
View directory record Official record
Conditions
Systemic Lupus Erthematosus (SLE)
Interventions
2-HOBA acetate (2-Hydroxybenzlamine acetate), Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Completed No phase listed Observational

A Non-drug Study Profiling Cutaneous Lupus

NCT01923415
View directory record Official record
Conditions
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
Interventions
No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
Procedure
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Indianapolis, Indiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 28, 2026, 8:08 AM EDT
Completed No phase listed Observational

Prospective Observational Study on the Incidence of Opportunistic Fungal Infections

NCT05707156
View directory record Official record
Conditions
Pneumocystis Jirovecii Infection, Pneumocystis, Cryptococcosis, Candidiasis, Aspergillosis
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
12,032 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 28, 2026, 8:08 AM EDT
Withdrawn Phase 1 Interventional

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

NCT06429800
View directory record Official record
Conditions
Lupus Nephritis, Systemic Lupus Erythematosus
Interventions
ATA3219
Drug
Lead sponsor
Atara Biotherapeutics
Industry
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Thousand Oaks, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 28, 2026, 8:08 AM EDT
Completed No phase listed Observational

Anti-Inflammatory Effects of Time-Restricted Feeding

NCT04728165
View directory record Official record
Conditions
Psoriasis, Systemic Inflammation
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 80 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 28, 2026, 8:08 AM EDT
Completed No phase listed Observational Results available

Effect of Emergency Department Care Reorganization on Door-to-antibiotic Times for Sepsis (LDS SWARM)

NCT03226366
View directory record Official record
Conditions
Septic Shock, Sepsis
Interventions
Immediate evaluation by multidisciplinary team
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
3,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
4
States / cities
Murray, Utah • Riverton, Utah • Salt Lake City, Utah + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2020 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

Topically Applied IDP-118 Lotion and HP Monad Lotion in Subjects With Moderate to Severe Plaque Psoriasis

NCT03058744
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-118 Lotion, HP Monad Lotion, Ultravate Cream, Tazorac Cream
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Anaheim, California • Encino, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2017 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Not applicable Interventional

UVA1 Light for Treatment of Scleroderma and Similar Conditions

NCT00476801
View directory record Official record
Conditions
Scleroderma, Keloids, Other Fibrosing Conditions
Interventions
German manufactured UVA1 light emitting device
Device
Lead sponsor
University of Michigan
Other
Eligibility
10 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 10, 2015 · Synced Oct 28, 2026, 8:08 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 28, 2026, 8:08 AM EDT